PMID: 30975858 Title: Glycosidase and glycan polymorphism control hydrolytic release of immunogenic flagellin peptides Product/Service Type: Custom Gene Synthesis Service Nature , 577: 689-694
, , , , , B12, , , ,
The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal
Drugs that interfere with fat absorption, such as orlistat (Alli, Xenical) can lead to oily spotting, gas, and soft stools
The emphasis of this page is therefore on catalog clarity, research-only designation, and practical logistics rather than any claim regarding biological application or outcome